Loading...
•
Dec 31, 2023
Moleculin Q4 2023 Earnings Report
Reported financial results for the full year 2023, highlighted by Annamycin's clinical data and a registered direct offering to extend cash runway.
Key Takeaways
Moleculin Biotech reported its full year 2023 financial results, emphasizing the growing body of positive clinical data for Annamycin and the extension of its cash runway into the fourth quarter of 2024 through a registered direct offering. The company is focused on advancing its pipeline programs toward key data milestones.
Established a significant growing body of positive clinical and encouraging safety data for Annamycin.
Closed a registered direct offering for gross proceeds of $4.5 million, extending the company's cash runway into the fourth quarter of 2024.
Presented positive interim data from the Phase 1B/2 clinical trial evaluating Annamycin for the treatment of AML at ASH.
Focused on driving priority pipeline programs toward key data milestones.
Forward Guidance
The company believes that its current cash and cash equivalents are sufficient to meet its projected operating requirements into the fourth quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...